You are here: Home » About Us » Management Team
President and Chief Executive Officer
Jan Keltjens joined Endosense as president and chief executive officer in September 2011, bringing to the company two decades of global leadership experience in the medical device and technology sectors. Prior to Endosense, he served as chief executive officer of AngioDynamics Inc. (NASDAQ: ANGO) as well as CryoCath Technologies Inc., which was acquired by Medtronic under his leadership in 2008 (now Medtronic CryoCath). Jan has also held a number of senior leadership positions at Cordis, a Johnson & Johnson company and Unilever, with global responsibilities spanning sales, marketing, operations, finance, and research and development. Jan graduated from St. Thomas College in Venlo, The Netherlands, and earned a secondary degree in physics from the University of Eindhoven, The Netherlands.
Co-founder and Chief Technology Officer
Giovanni Leo co-founded Endosense in 2003 to develop novel technology for the catheter ablation treatment of cardiac arrhythmias. Mr. Leo brings to Endosense significant management and engineering experience in the fields of brachytherapy and particle accelerator control systems. Prior to Endosense, Mr. Leo was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific-funded medical device company that developed the only European system for vascular brachytherapy. He was also co-founder of Isotopes and Metals Ltd., an emerging medical device company focused on technology for prostate and gynecological brachytherapy. Isotopes and Metals’ products are now sold by Philips Medical Systems. Mr. Leo previously held a software quality manager position at LeCroy Corp. as well as a CERN fellowship in the Accelerator Technology, Industrial Controls Group. Mr. Leo earned a degree in management engineering from Politecnico of Milano, Italy, following his education at the European School of Varese, Italy.
Chief Financial Officer
Andrea Buscaglia brings to Endosense more than 20 years of senior financial experience in the biopharmaceutical, investment banking and accounting sectors. Before joining Endosense, he was chief financial officer of Nitec Pharma AG, a private Basel, Switzerland-based specialty pharmaceutical company. Prior to this, Mr. Buscaglia held various officer-level positions at Geneva-based biotech company Serono (now part of the Merck KGaA Group), including vice president of corporate finance and vice president of corporate development within the company’s business development group. While at Serono, Mr. Buscaglia played a pivotal role in a $2 billion equity offering and New York Stock Exchange listing, as well as investor relations, mergers and acquisitions, and licensing activities. Mr. Buscaglia came to the biopharmaceutical sector following eight years as an investment banker at S.G. Warburg (now UBS) and Deutsche Bank, where he participated in various equity capital markets transactions, including initial public offerings, secondary offerings and public tender offers, and mergers and acquisitions. He began his career as an auditor at Arthur Andersen & Co. Mr. Buscaglia holds a degree in business administration from Bocconi University in Milan.
Hendrik Lambert, Ph.D.
Vice President Clinical and Regulatory Affairs
Hendrik Lambert is a clinical engineering professional with deep experience in cardiac and vascular medical devices. Prior to Endosense, he spent eight years at Guidant Corporation, where he was most recently responsible for the company’s Institute for Therapy Advancement. Under his tenure, the Institute implemented 160 training courses per year, training more than 1,600 physician customers and 300 employees, and it became the first privately sponsored training center to organize courses as part of continuing medical education (CME) accreditation. Mr. Lambert also held various roles of increasing responsibility at Guidant, including manager of field clinical engineers and European clinical and research manager. Mr. Lambert previously held numerous clinical engineering positions with InControl, an emerging medical device company focused on the treatment of atrial fibrillation. Under his tenure, the company received a CE Mark for its Metrix implantable defibrillator. Mr. Lambert earned master’s degrees in electronic engineering and biomedical engineering as well as a Ph.D. in biomedical engineering from the University of Ghent, Belgium.
David Enfrun has built up leadership in medical device manufacturing through 10 years of technical management in industrial manufacturing. Before joining Endosense, he served as an operations manager at Anteis SA, an injectable medical device company, where he enhanced the manufacturing unit acting as site director, implementing manufacturing and multi-site planning and sourcing processes, managing and developing the company’s manufacturing resources for growth, and also leading the corresponding support functions. Under Mr. Enfrun’s leadership, the company’s production output increased by a factor of six. Mr. Enfrun previously held a manufacturing manager position at Corneal S.A. (France), specializing in medical devices for ocular surgery.
Mr. Enfrun obtained a master’s degree in engineering from the Ecole Nationale Supérieure d’ Arts et Métiers, Paris.